Why Synta Pharmaceuticals Is Poised to Plunge

Before you go, we thought you'd like these...
Before you go close icon

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biopharmaceutical company Synta Pharmaceuticals has received the dreaded one-star ranking.

With that in mind, let's take a closer look at Synta and see what CAPS investors are saying about the stock right now.

Syntafacts

Headquarters (founded)

Lexington, Mass. (2000)

Market Cap

$613.9 million

Industry

Biotechnology

Trailing-12-Month Revenue

$3.6 million

Management

Co-Founder/CEO Dr. Safi Bahcall
CFO Keith Ehrlich

Return on Capital (average, past 3 years)

(67%)

Cash/Debt

$55.1 million / $14.4 million

Competitors

Infinity Pharmaceuticals
Novartis


Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 22% of the 37 All-Star members who have rated Synta believe the stock will underperform the S&P 500 going forward.

Just yesterday, one of those Fools, zzlangerhans, touched on the stock's seemingly unsustainable valuation:

Too much too soon for Synta, a stock enjoying the 2013 biopharma rocket effect. Ganetespib has proven very little so far, and certainly not enough to justify a [$650M] market cap. Management has been taking full advantage of the precipitous increase in stock value with dilutive financings to ensure that their salaries will be around for years even of ganetespib fails miserably. We shouldn't have much longer to wait with topline PFS and OS data from the phase II portion of the GALAXY trial of ganetespib in advanced NSCLC expected later this year. I'm expecting a heavy emphasis on subset analyses.

If you want market-topping returns, you need to protect your portfolio from any undue risk. Luckily, we've found another stock we are incredibly excited about -- excited enough to dub it "The Motley Fool's Top Stock for 2013." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.

Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.

The article Why Synta Pharmaceuticals Is Poised to Plunge originally appeared on Fool.com.

Fool contributor Brian Pacampara has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners